eric
02-28-2008, 07:10 PM
http://www.therapeuticsdaily.com/news/article.cfm?contenttype=sentryarticle&contentvalue=1736583&channelID=28
The agent, named cis-APP, has shown a high degree of anticancer efficacy in rodent models, and appears not to induce any adverse side effects.
Yissum's chief executive, Nava Sofer, said: "this new class of drugs could potentially change the lives of millions of cancer patients by providing protection from metastasis in the form of a pill."
The agent, named cis-APP, has shown a high degree of anticancer efficacy in rodent models, and appears not to induce any adverse side effects.
Yissum's chief executive, Nava Sofer, said: "this new class of drugs could potentially change the lives of millions of cancer patients by providing protection from metastasis in the form of a pill."